Long-term survival of <i>NPM1</i> AML treated with intensive chemotherapy with extensive molecular data available-Reference-Cited by-同舟云学术

Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available

Published:2024-02-08 Issue:5 Volume:65 Page:700-703
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Garciaz Sylvain¹,Berton Guillaume¹,Hospital Marie-Anne¹,Guille Arnaud²,Adélaïde José²,Saillard Colombe¹,Hicheri Yosr¹,Mozziconacci Marie-Joëlle³,Duprez Estelle⁴,Récher Christian⁵⁶,Alary Anne-Sophie⁷,Birnbaum Daniel²,Vey Norbert¹

Affiliation:

1. Department of Hematology, Institut Paoli-Calmettes, INSERM UMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France

2. Predictive Oncology Laboratory, Marseille Cancer Research Center, INSERMUMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France

3. Department of Biopathology, Institut Paoli-Calmettes, Marseille, France

4. Epigenetic Factors in Normal and Malignant Hematopoiesis, Marseille Cancer Research Center, INSERMUMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France

5. Department of Hematology, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France

6. Université Toulouse III Paul Sabatier, Cancer Research Center of Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France

7. Department of Cancer Biology, Institut Paoli-Calmettes, Marseille, France

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2312430

Reference17 articles.

1. Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype

2. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

3. Genomic Classification and Prognosis in Acute Myeloid Leukemia

4. Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia

5. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia